Mechanistic insights into the anti-benign prostatic hyperplasia effect of dihydromyricetin via suppression of the 5-AR/TGF-β1/Smad2 axis
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026
DOI: 10.1007/s00210-026-04998-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Sarah Sameh Abd El-Hameed und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Toxicology, Faculty of Pharmacy, Minia University, Minia, Egypt. sara.sameh@minia.edu.eg. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Transforming Growth Factor beta1, Flavonols, Smad2 Protein. Die Arbeit nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Minia University.
Abstract (Originalsprache)
Benign prostatic hyperplasia (BPH) is a noncancerous prostate enlargement that significantly impacts the quality of life in aged men. Both oxidative stress and inflammation interplay to induce hyperplasia of prostatic epithelial cells as well as seminal vesicle tissues. Dihydromyricetin (DHM), extracted from Ampelopsis grossedentata , is used in traditional Chinese medicine for hundreds of years. It exhibited prominent anticancer, anti-inflammatory, and antioxidant activities in several models. To date, its potential protective effects for BPH have not been investigated. The aim of this study was to investigate the role of DHM in the management of testosterone-induced proliferation in prostate and seminal vesicle tissues. Male Wistar rats (200 to 250 g) were divided into three groups: a control group receiving sesame oil (the vehicle), a BPH group receiving testosterone oenanthate (3 mg/kg, subcutaneously) daily for 4 weeks to induce hyperplasia, and a DHM group receiving DHM (50 mg/kg) alongside testosterone oenanthate (3 mg/kg). DHM significantly reduced the prostate and seminal vesicle weights, ameliorated the histopathological changes induced by testosterone, and nearly normalized the serum testosterone, FSH, and LH levels. It also reduced the serum PSA level. Further, DHM reduced MDA levels while increasing GSH levels. Besides, it reduced the prostatic levels of 5-alpha reductase and attenuated TGF-β1/Smad-2 pathway. The anti-hyperproliferation and the anti-inflammatory effects of DHM were attributed to the attenuation of the expression of PCNA, procaspase-3, iNOS, TLR-4, and IL-1β in both the prostate and seminal vesicle tissues. DHM has potential protective effects against testosterone-induced BPH model via downregulation of inflammatory mediators, restoration of oxidative balance, and induction of cell apoptosis. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology & Toxicology, Faculty of Pharmacy, Minia University, Minia, Egypt. sara.sameh@minia.edu.eg.
- Department of Pharmacology & Toxicology, Faculty of Pharmacy, Minia University, Minia, Egypt.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia National University (MNU), Minia, Egypt.
- Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia, Egypt.
- Department of Pharmacology, College of Pharmacy, King Khalid University, Abha, 62521, Saudi Arabia.
Förderung
- Minia University
Zitieren
APA
El-Hameed, S. S. A., Matouk, A. I., Ibrahim, A. R. N., & El-Daly, M. (2026). Mechanistic insights into the anti-benign prostatic hyperplasia effect of dihydromyricetin via suppression of the 5-AR/TGF-β1/Smad2 axis. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-04998-3
Vancouver
El-Hameed SSA, Matouk AI, Ibrahim ARN, El-Daly M. Mechanistic insights into the anti-benign prostatic hyperplasia effect of dihydromyricetin via suppression of the 5-AR/TGF-β1/Smad2 axis. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-04998-3
BibTeX
@article{ElHameed2026,
author = {El-Hameed, Sarah Sameh Abd and Matouk, Asmaa I and Ibrahim, Ahmed R N and El-Daly, Mahmoud},
title = {Mechanistic insights into the anti-benign prostatic hyperplasia effect of dihydromyricetin via suppression of the 5-AR/TGF-β1/Smad2 axis},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-026-04998-3}
}
EUVIMED